First Time Loading...

Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 99.2 EUR 0.1%
Updated: May 9, 2024

Intrinsic Value

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. [ Read More ]

The intrinsic value of one BIM stock under the Base Case scenario is 98.09 EUR. Compared to the current market price of 99.2 EUR, Biomerieux SA is Overvalued by 1%.

Key Points:
BIM Intrinsic Value
Base Case
98.09 EUR
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biomerieux SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BIM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Biomerieux SA

Provide an overview of the primary business activities
of Biomerieux SA.

What unique competitive advantages
does Biomerieux SA hold over its rivals?

What risks and challenges
does Biomerieux SA face in the near future?

Summarize the latest earnings call
of Biomerieux SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biomerieux SA.

Provide P/S
for Biomerieux SA.

Provide P/E
for Biomerieux SA.

Provide P/OCF
for Biomerieux SA.

Provide P/FCFE
for Biomerieux SA.

Provide P/B
for Biomerieux SA.

Provide EV/S
for Biomerieux SA.

Provide EV/GP
for Biomerieux SA.

Provide EV/EBITDA
for Biomerieux SA.

Provide EV/EBIT
for Biomerieux SA.

Provide EV/OCF
for Biomerieux SA.

Provide EV/FCFF
for Biomerieux SA.

Provide EV/IC
for Biomerieux SA.

Show me price targets
for Biomerieux SA made by professional analysts.

What are the Revenue projections
for Biomerieux SA?

How accurate were the past Revenue estimates
for Biomerieux SA?

What are the Net Income projections
for Biomerieux SA?

How accurate were the past Net Income estimates
for Biomerieux SA?

What are the EPS projections
for Biomerieux SA?

How accurate were the past EPS estimates
for Biomerieux SA?

What are the EBIT projections
for Biomerieux SA?

How accurate were the past EBIT estimates
for Biomerieux SA?

Compare the revenue forecasts
for Biomerieux SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biomerieux SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biomerieux SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biomerieux SA compared to its peers.

Compare the P/E ratios
of Biomerieux SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Biomerieux SA with its peers.

Analyze the financial leverage
of Biomerieux SA compared to its main competitors.

Show all profitability ratios
for Biomerieux SA.

Provide ROE
for Biomerieux SA.

Provide ROA
for Biomerieux SA.

Provide ROIC
for Biomerieux SA.

Provide ROCE
for Biomerieux SA.

Provide Gross Margin
for Biomerieux SA.

Provide Operating Margin
for Biomerieux SA.

Provide Net Margin
for Biomerieux SA.

Provide FCF Margin
for Biomerieux SA.

Show all solvency ratios
for Biomerieux SA.

Provide D/E Ratio
for Biomerieux SA.

Provide D/A Ratio
for Biomerieux SA.

Provide Interest Coverage Ratio
for Biomerieux SA.

Provide Altman Z-Score Ratio
for Biomerieux SA.

Provide Quick Ratio
for Biomerieux SA.

Provide Current Ratio
for Biomerieux SA.

Provide Cash Ratio
for Biomerieux SA.

What is the historical Revenue growth
over the last 5 years for Biomerieux SA?

What is the historical Net Income growth
over the last 5 years for Biomerieux SA?

What is the current Free Cash Flow
of Biomerieux SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biomerieux SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biomerieux SA

Current Assets 2.2B
Cash & Short-Term Investments 65.3m
Receivables 944.3m
Other Current Assets 1.2B
Non-Current Assets 3.1B
Long-Term Investments 220.2m
PP&E 1.5B
Intangibles 1.2B
Other Non-Current Assets 100.4m
Current Liabilities 1.1B
Accounts Payable 265.1m
Short-Term Debt 10m
Other Current Liabilities 812.2m
Non-Current Liabilities 419.7m
Long-Term Debt 355.4m
Other Non-Current Liabilities 64.3m
Efficiency

Earnings Waterfall
Biomerieux SA

Revenue
3.7B EUR
Cost of Revenue
-1.6B EUR
Gross Profit
2.1B EUR
Operating Expenses
-1.6B EUR
Operating Income
439m EUR
Other Expenses
-81.4m EUR
Net Income
357.6m EUR

Free Cash Flow Analysis
Biomerieux SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BIM Profitability Score
Profitability Due Diligence

Biomerieux SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive Operating Income
57/100
Profitability
Score

Biomerieux SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

BIM Solvency Score
Solvency Due Diligence

Biomerieux SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
69/100
Solvency
Score

Biomerieux SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIM Price Targets Summary
Biomerieux SA

Wall Street analysts forecast BIM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIM is 116.66 EUR with a low forecast of 90.9 EUR and a high forecast of 134.4 EUR.

Lowest
Price Target
90.9 EUR
8% Downside
Average
Price Target
116.66 EUR
18% Upside
Highest
Price Target
134.4 EUR
35% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BIM Price
Biomerieux SA

1M 1M
-7%
6M 6M
+6%
1Y 1Y
+5%
3Y 3Y
+6%
5Y 5Y
+43%
10Y 10Y
+292%
Annual Price Range
99.2
52w Low
85.9
52w High
106.2
Price Metrics
Average Annual Return 11.87%
Standard Deviation of Annual Returns 28.66%
Max Drawdown -44%
Shares Statistics
Market Capitalization 11.7B EUR
Shares Outstanding 118 160 000
Percentage of Shares Shorted
N/A

BIM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Biomerieux SA Logo
Biomerieux SA

Country

France

Industry

Health Care

Market Cap

11.7B EUR

Dividend Yield

0.85%

Description

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 13,076 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Contact

AUVERGNE-RHONE-ALPES
Craponne
5, rue des Aqueducs
+33478872000.0
http://www.biomerieux.fr/

IPO

2004-06-07

Employees

13 076

Officers

Chief Executive Officer
Mr. Pierre Boulud
Executive VP of Purchasing and Information Systems & CFO
Mr. Guillaume Bouhours
Investor Relations
Sylvain Morgeau
Executive Vice President of Legal, Corporate Integrity & Public Affairs
Ms. Audrey Dauvet
Executive Vice President of Human Resources, Communications & CSR
Ms. Valerie Leylde
Executive Vice President of Global Quality, Manufacturing & Supply Chain
Mr. Pierre Charbonnier
Show More
Executive Vice President of Industrial Applications
Mr. Yasha Mitrotti
Head of CSR
Mr. Frederic Beseme
Executive Vice President of Clinical Operations
Jennifer Zinn
Executive VP & Chief Medical Officer
Charles K. Cooper
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIM stock?

The intrinsic value of one BIM stock under the Base Case scenario is 98.09 EUR.

Is BIM stock undervalued or overvalued?

Compared to the current market price of 99.2 EUR, Biomerieux SA is Overvalued by 1%.